According to people close to the matter, Valeant Pharmaceuticals (NYSE:VRX) is currently negotiating with Germany's Carl Zeiss Meditec to sell its Bausch + Lomb unit's surgical products business, which could fetch $2B.
Selling assets is one way Valeant is paying down debt.
Last November, Allergan and TPG were rumored to be suitors for the business but nothing happened.
Valeant is off a fraction premarket.
Now read: Valeant Will Bounce Back To $10 »
Subscribe for full text news in your inbox